Trials / Completed
CompletedNCT04577612
A Randomized Controlled Test of the Effects of CHI-554 on Fear.
A Randomized Controlled Test of the Effects of CHI-554 on Fear (F-01)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Canopy Growth Corporation · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled phase 2b clinical trial examining the effects of CHI-554 (CBD) on Fear (F-01)
Detailed description
This study will examine the potential of a novel formulation of hemp-derived CBD (CHI-554) to reduce fear elicited via a safe, well-established, controlled, laboratory-based carbon dioxide (CO2)-enriched air biological challenge that causes abrupt increases in bodily arousal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHI-554 | hemp-derived CBD in MCT oil |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2021-05-15
- Completion
- 2021-05-25
- First posted
- 2020-10-08
- Last updated
- 2021-06-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04577612. Inclusion in this directory is not an endorsement.